1	A	A	B-NP	DT	O	6	NMOD	0
2	novel	novel	I-NP	JJ	O	6	NMOD	0
3	integrin	integrin	I-NP	NN	B-protein	6	NMOD	0
4	alpha5beta1	alpha5beta1	I-NP	NN	I-protein	6	NMOD	0
5	antagonistic	antagonistic	I-NP	JJ	O	6	NMOD	0
6	peptide	peptide	I-NP	NN	O	8	NMOD	0
7	,	,	O	,	O	8	P	0
8	A5-1	A5-1	B-NP	NN	B-protein	0	ROOT	0
9	,	,	O	,	O	8	P	0
10	screened	screen	B-VP	VBN	O	8	NMOD	0
11	by	by	B-PP	IN	O	10	VMOD	0
12	Protein	Protein	B-NP	NN	O	14	NMOD	0
13	Chip	Chip	I-NP	NN	O	14	NMOD	0
14	system	system	I-NP	NN	O	11	PMOD	0
15	as	as	B-PP	IN	O	10	VMOD	0
16	a	a	B-NP	DT	O	19	NMOD	0
17	potent	potent	I-NP	JJ	O	19	NMOD	0
18	angiogenesis	angiogenesis	I-NP	NN	O	19	NMOD	3	angiogenesis
19	inhibitor	inhibitor	I-NP	NN	O	15	PMOD	0
20	.	.	O	.	O	8	P	0

1	Integrin	Integrin	B-NP	NN	B-protein	2	NMOD	0
2	alpha5beta1	alpha5beta1	I-NP	NN	I-protein	7	SUB	0
3	immobilized	immobilize	B-VP	VBN	O	2	NMOD	0
4	on	on	B-PP	IN	O	3	VMOD	0
5	a	a	B-NP	DT	O	6	NMOD	0
6	ProteoChip	ProteoChip	I-NP	NN	O	4	PMOD	0
7	was	be	B-VP	VBD	O	0	ROOT	0
8	used	use	I-VP	VBN	O	7	VC	0
9	to	to	B-VP	TO	O	10	VMOD	0
10	screen	screen	I-VP	VB	O	7	VMOD	0
11	new	new	B-NP	JJ	O	13	NMOD	0
12	antagonistic	antagonistic	I-NP	JJ	O	13	NMOD	0
13	peptides	peptide	I-NP	NNS	O	10	OBJ	0
14	from	from	B-PP	IN	O	10	VMOD	0
15	multiple	multiple	B-NP	JJ	O	17	NMOD	0
16	hexapeptide	hexapeptide	I-NP	NN	O	17	NMOD	0
17	sub-libraries	sub-library	I-NP	NNS	O	14	PMOD	0
18	of	of	B-PP	IN	O	17	NMOD	0
19	the	the	B-NP	DT	O	25	NMOD	0
20	positional	positional	I-NP	JJ	O	25	NMOD	0
21	scanning	scanning	I-NP	NN	O	25	NMOD	0
22	synthetic	synthetic	I-NP	JJ	O	25	NMOD	0
23	peptide	peptide	I-NP	NN	O	25	NMOD	0
24	combinatorial	combinatorial	I-NP	JJ	O	25	NMOD	0
25	library	library	I-NP	NN	O	18	PMOD	0
26	(	(	O	(	O	28	DEP	0
27	PS-SPCL	PS-SPCL	B-NP	NN	B-protein	28	DEP	0
28	)	)	O	)	O	25	NMOD	0
29	.	.	O	.	O	7	P	0

1	The	The	B-NP	DT	O	4	NMOD	0
2	integrin	integrin	I-NP	NN	B-protein	4	NMOD	0
3	alpha5beta1-Fibronectin	alpha5beta1-Fibronectin	I-NP	NN	I-protein	4	NMOD	0
4	interaction	interaction	I-NP	NN	O	5	SUB	15	interaction
5	was	be	B-VP	VBD	O	0	ROOT	0
6	demonstrated	demonstrate	I-VP	VBN	O	5	VC	0
7	on	on	B-PP	IN	O	6	VMOD	0
8	the	the	B-NP	DT	O	9	NMOD	0
9	chip	chip	I-NP	NN	O	7	PMOD	0
10	.	.	O	.	O	5	P	0

1	A	A	B-NP	DT	O	4	NMOD	0
2	novel	novel	I-NP	JJ	O	4	NMOD	0
3	peptide	peptide	I-NP	NN	O	4	NMOD	0
4	ligand	ligand	I-NP	NN	O	17	SUB	0
5	,	,	O	,	O	17	P	0
6	A5-1	A5-1	B-NP	NN	B-protein	17	SUB	0
7	(	(	O	(	O	9	DEP	0
8	VILVLF	VILVLF	B-NP	NN	B-protein	9	DEP	0
9	)	)	O	)	O	6	NMOD	0
10	,	,	O	,	O	6	P	0
11	with	with	B-PP	IN	O	6	NMOD	0
12	high	high	B-NP	JJ	O	13	NMOD	0
13	affinity	affinity	I-NP	NN	O	11	PMOD	0
14	to	to	B-PP	TO	O	13	NMOD	0
15	integrin	integrin	B-NP	NN	B-protein	16	NMOD	0
16	alpha5beta1	alpha5beta1	I-NP	NN	I-protein	14	PMOD	0
17	was	be	B-VP	VBD	O	0	ROOT	0
18	identified	identify	I-VP	VBN	O	17	VC	0
19	from	from	B-PP	IN	O	18	VMOD	0
20	the	the	B-NP	DT	O	22	NMOD	0
21	hexapeptide	hexapeptide	I-NP	NN	B-DNA	22	NMOD	0
22	libraries	library	I-NP	NNS	I-DNA	19	PMOD	0
23	with	with	B-PP	IN	O	22	NMOD	0
24	this	this	B-NP	DT	O	27	NMOD	0
25	chip-based	chip-based	I-NP	JJ	O	27	NMOD	0
26	screening	screening	I-NP	NN	O	27	NMOD	0
27	method	method	I-NP	NN	O	23	PMOD	0
28	on	on	B-PP	IN	O	27	NMOD	0
29	the	the	B-NP	DT	O	30	NMOD	0
30	basis	basis	I-NP	NN	O	28	PMOD	0
31	of	of	B-PP	IN	O	30	NMOD	0
32	a	a	B-NP	DT	O	35	NMOD	0
33	competitive	competitive	I-NP	JJ	O	35	NMOD	0
34	inhibition	inhibition	I-NP	NN	O	35	NMOD	0
35	assay	assay	I-NP	NN	O	31	PMOD	0
36	.	.	O	.	O	17	P	0

1	A5-1	A5-1	B-NP	NN	B-protein	2	SUB	0
2	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	18	inhibits
3	the	the	B-NP	DT	O	5	NMOD	0
4	integrin-fibronectin	integrin-fibronectin	I-NP	JJ	O	5	NMOD	0
5	interaction	interaction	I-NP	NN	O	17	NMOD	15	interaction
6	in	in	B-PP	IN	O	5	NMOD	0
7	a	a	B-NP	DT	O	9	NMOD	0
8	dose-dependent	dose-dependent	I-NP	JJ	O	9	NMOD	0
9	manner	manner	I-NP	NN	O	6	PMOD	0
10	(	(	O	(	O	17	NMOD	0
11	IC	IC	B-NP	NN	O	17	NMOD	0
12	(	(	O	(	O	14	DEP	0
13	50	50	B-NP	CD	O	14	DEP	0
14	)	)	O	)	O	11	NMOD	0
15	;	;	O	:	O	17	P	0
16	1.56+/-0.28	1.56+/-0.28	B-NP	CD	O	17	NMOD	0
17	microM	microM	I-NP	NN	O	2	OBJ	0
18	.	.	O	.	O	2	P	0

1	In	In	B-PP	IN	O	5	VMOD	0
2	addition	addition	B-NP	NN	O	1	PMOD	0
3	,	,	O	,	O	5	P	0
4	it	it	B-NP	PRP	O	5	SUB	0
5	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	18	inhibits
6	human	human	B-NP	JJ	B-cell_type	11	NMOD	0
7	umbilical	umbilical	I-NP	JJ	I-cell_type	11	NMOD	0
8	vein	vein	I-NP	NN	I-cell_type	11	NMOD	0
9	endothelial	endothelial	I-NP	JJ	I-cell_type	11	NMOD	0
10	cell	cell	I-NP	NN	I-cell_type	11	NMOD	0
11	proliferation	proliferation	I-NP	NN	O	23	NMOD	1	proliferation
12	,	,	O	,	O	23	P	0
13	migration	migration	B-NP	NN	O	23	NMOD	14	migration
14	,	,	O	,	O	23	P	0
15	adhesion	adhesion	B-NP	NN	O	23	NMOD	15	adhesion
16	,	,	O	,	O	23	P	0
17	tubular	tubular	B-NP	JJ	O	19	NMOD	0
18	network	network	I-NP	NN	O	19	NMOD	0
19	formation	formation	I-NP	NN	O	23	NMOD	2	formation
20	,	,	O	,	O	23	P	0
21	and	and	O	CC	O	23	NMOD	0
22	bFGF-induced	bFGF-induced	B-NP	JJ	O	23	NMOD	17	induced
23	neovascularization	neovascularization	I-NP	NN	O	5	OBJ	3	neovascularization
24	in	in	B-PP	IN	O	23	NMOD	0
25	a	a	B-NP	DT	O	28	NMOD	0
26	chick	chick	I-NP	NN	O	28	NMOD	0
27	chorioallantoic	chorioallantoic	I-NP	JJ	O	28	NMOD	0
28	membrane	membrane	I-NP	NN	O	24	PMOD	0
29	.	.	O	.	O	5	P	0

1	These	These	B-NP	DT	O	2	NMOD	0
2	results	result	I-NP	NNS	O	3	SUB	0
3	suggest	suggest	B-VP	VBP	O	0	ROOT	0
4	that	that	B-SBAR	IN	O	3	VMOD	0
5	A5-1	A5-1	B-NP	NN	B-protein	6	SUB	0
6	will	will	B-VP	MD	O	4	SBAR	0
7	be	be	I-VP	VB	O	6	VC	0
8	a	a	B-NP	DT	O	10	NMOD	0
9	potent	potent	I-NP	JJ	O	10	NMOD	0
10	inhibitor	inhibitor	I-NP	NN	O	7	PRD	0
11	of	of	B-PP	IN	O	10	NMOD	0
12	neovascularization	neovascularization	B-NP	NN	O	11	PMOD	3	neovascularization
13	.	.	O	.	O	3	P	0

